New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer

Progastrin-releasing peptide (ProGRP) is a potential marker for small-cell lung cancer (SCLC) in serum; however, it may be more stable in plasma. We investigated a new plasma assay (ProGRPp) and its usefulness in diagnosing and monitoring SCLC. The marker concentrations were determined on the ARCHIT...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2016-02, Vol.114 (4), p.469-476
Main Authors: Nisman, Benjamin, Nechushtan, Hovav, Biran, Haim, Peled, Nir, Gantz-Sorotsky, Hadas, Doviner, Victoria, Perelman, Marina, Bar, Jair, Onn, Amir, Uziely, Beatrice, Peretz, Tamar
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - blood
Case-Control Studies
Diagnosis, Differential
Female
Humans
Lung Neoplasms - blood
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Male
Middle Aged
Molecular Diagnostics
Monitoring, Physiologic - methods
Peptide Fragments - blood
Recombinant Proteins
Small Cell Lung Carcinoma - blood
Small Cell Lung Carcinoma - diagnosis
Small Cell Lung Carcinoma - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Progastrin-releasing peptide (ProGRP) is a potential marker for small-cell lung cancer (SCLC) in serum; however, it may be more stable in plasma. We investigated a new plasma assay (ProGRPp) and its usefulness in diagnosing and monitoring SCLC. The marker concentrations were determined on the ARCHITECT i system. The assay could distinguish SCLC from non-small-cell lung cancer (NSCLC: area under the curve 0.931, 95% CI 0.893-0.969; cross-validated accuracy 0.813; sensitivity 84.0%, specificity 96.3%; at 140 pg ml(-1) cutoff). The probability of SCLC when ProGRPp was >140 pg ml(-1) was 91.8%, after adjusting for age, gender, and renal dysfunction. The NSCLC patients with ProGRPp >140 pg ml(-1) were at high risk (odds ratio=37.0, P
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2016.7